Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akili, Inc.AKLI · Entity 89130 | Director | May 02, 2023 | May 04, 2023 |
| Annexon, Inc.ANNX · Entity 5011 | Director | June 11, 2026 | June 15, 2026 |
| Apnimed, Inc.APMD · Entity 4910 | Director | July 30, 2026 | August 03, 2026 |
| Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269 | CCO-Migraine & Common Disease | October 03, 2022 | October 03, 2022 |
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | Chief Commercial Officer | January 07, 2025 | January 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akili, Inc.
Report date May 02, 2023 · Filed May 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.09 · Expires 2033-05-02 | Direct | 22,000 |
Reported balance
After 2023-05-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-02 · Grant · Acquired 22,000 · Balance 22,000 F1: The shares underlying this option shall vest in full upon the earlier of (i) May 2, 2024 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest in full upon the earlier of (i) May 2, 2024 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.
Annexon, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2036-06-11 | Direct | 65,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 65,000 · Balance 65,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date.
Apnimed, Inc.
Report date July 30, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 44,477 |
Reported balance
After 2026-07-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-30 · Grant · Acquired 44,477 · Balance 44,477 F2: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-03 · Disposition to issuer · Acquired 44,477 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 44,477 |
Reported balance
After 2026-08-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-03 · Grant · Acquired 44,477 · Balance 44,477 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.
F2: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.
Biohaven Pharmaceutical Holding Co Ltd.
Report date October 03, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 1
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 14,226 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). |
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-03 · Disposition to issuer · Disposed 11,250 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-03 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-03 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.69 · Expires 2032-01-07 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-03 · Disposition to issuer · Disposed 775 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.69 · Expires 2032-01-07 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-03 · Disposition to issuer · Disposed 29,225 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.32 · Expires 2031-01-06 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-10-03 · Disposition to issuer · Disposed 2,398 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.32 · Expires 2031-01-06 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-10-03 · Disposition to issuer · Disposed 37,602 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.99 · Expires 2029-11-25 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-10-03 · Disposition to issuer · Disposed 1,742 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.99 · Expires 2029-11-25 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-10-03 · Disposition to issuer · Disposed 28,258 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.47 · Expires 2029-04-01 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-10-03 · Disposition to issuer · Disposed 5,913 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.47 · Expires 2029-04-01 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-10-03 · Disposition to issuer · Disposed 44,087 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").
F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").
F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.
F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
NewAmsterdam Pharma Co N.V.
Report date January 07, 2025 · Filed January 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 43,000 |
Reported balance
After 2025-01-07 transaction · row 1
1 source rowRow 1 · 2025-01-07 · Grant · Acquired 43,000 · Balance 43,000 F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date. F2: Each RSU was granted on January 7, 2025 for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date.
F2: Each RSU was granted on January 7, 2025 for no consideration.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apogee Therapeutics, Inc.
Report date September 03, 2026 · Filed September 03, 2026
Section 16 reporting ended · disclosed 2026-09-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 1
1 source rowRow 1 · 2026-09-03 · Disposition to issuer · Disposed 34,824 · Balance 0 F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.85 · Expires 2034-06-05 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-03 · Disposition to issuer · Disposed 10,370 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.66 · Expires 2035-06-17 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-03 · Disposition to issuer · Disposed 14,461 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.00 · Expires 2036-06-09 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-03 · Disposition to issuer · Disposed 7,657 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 02, 2020 Filed Nov 4, 2020 20:31 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 4,010 | $77.01 | $308,799.27 |
DisclosureSEC source: 0001562180-20-006560 · primarydocument.xml · nonDerivative · entry 3 JONES WILLIAM A JR · CIK 0001373097 · CCO-Migraine & Common Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,055 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.54 - $77.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:31 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 24,690 | $76.02 | $1,876,872.08 |
DisclosureSEC source: 0001562180-20-006560 · primarydocument.xml · nonDerivative · entry 2 JONES WILLIAM A JR · CIK 0001373097 · CCO-Migraine & Common Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,065 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.53 - $76.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 20:31 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 30,000 | $50.72 | $1,521,600.00 |
DisclosureSEC source: 0001562180-20-006560 · primarydocument.xml · nonDerivative · entry 1 JONES WILLIAM A JR · CIK 0001373097 · CCO-Migraine & Common Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,755 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:40 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionRestricted Share Unit Award · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001689813-19-000132 · wf-form4_157689603813307.xml · derivative · entry 3 JONES WILLIAM A JR · CIK 0001373097 · CCO-Migraine & Common Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd. F2 · price: Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd. F3 · derivative.exercise_date: The reporting person was granted 12,000 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:40 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Tax withholdingCommon Shares | 1,245 | $52.13 | $64,901.85 |
DisclosureSEC source: 0001689813-19-000132 · wf-form4_157689603813307.xml · nonDerivative · entry 2 JONES WILLIAM A JR · CIK 0001373097 · CCO-Migraine & Common Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,755 F1 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:40 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001689813-19-000132 · wf-form4_157689603813307.xml · nonDerivative · entry 1 JONES WILLIAM A JR · CIK 0001373097 · CCO-Migraine & Common Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:31 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantRestricted Share Unit Award · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001689813-19-000113 · wf-form4_157490829443108.xml · derivative · entry 2 JONES WILLIAM A JR · CIK 0001373097 · CCO-Migraine & Common Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Shares · 12,000 shares Expires 2022-11-24 F2 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd. F2 · price: Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd. F3 · derivative.exercise_date: The reporting person was granted 12,000 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:31 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $57.40 | $0.00 |
DisclosureSEC source: 0001689813-19-000113 · wf-form4_157490829443108.xml · derivative · entry 1 JONES WILLIAM A JR · CIK 0001373097 · CCO-Migraine & Common Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2029-11-24 F1 · derivative.exercise_date: The shares underlying this option vest in four equal installments on November 25, 2019, 2020, 2021 and 2022, subject to the optionholder's continuous service with the issuer at each vesting date. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:17 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantEmployee Stock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $50.72 | $0.00 |
DisclosureSEC source: 0001209191-19-023435 · doc4.xml · derivative · entry 1 JONES WILLIAM A JR · CIK 0001373097 · CCO-Migraine & Common Disease 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Shares · 80,000 shares Expires 2029-03-31 F1 · derivative.exercise_date: The shares underlying this option vest in three equal installments on April 1, 2019, April 1, 2020 and April 1, 2021, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.